• Proceedings of the KOR-BRONCHOESO Conference
• /
• 1987.05a
• /
• pp.23.1-23
• /
• 1987

1985년 1월부터 1986년 12월까지 전북의대 부속병원 이비인후과에 입원하여 수술치료를 받은 34예의 갑상선 결절을 가진 환자를 대상으로 임상분석을 실시하여 다음과 같은 결과를 얻었다. 1) 34례중 32례(94.1%)가 양성, 그리고 2례(5.9%)가 악성 결절이었다. 2) 성비는 33 : 1로 여성에서 월등히 많았다. 3) 20-40대가 25명(73.5%)였고, 40대가 11명(32.4%)로 가장 많았다. 4) 이병기간은 3개월 이내가 14명(41.1%)으로 가장 많았다. 5) 임상증상에서 결절 촉진 34례(100%), 피로감 6례(18%) 심계항진 5례(15%)순이었다. 6) 발생부위에서는 우엽 21례(62%), 좌엽 10례(29%), 양엽 2례(6%) isthmus 1례(3%)순이었다. 7) $I^{131}$섭취검사에서 73.9%가 정상범위였으며, 갑상선주사소견에서는 cold결절이 91.3%였다. 8) 병리조직학적 분류를 보면 양성에서는 adenema 24례(75%), adenomatous goiter 5례(16%), cyst 3례(9%)순이었고 악성 2례는 papillary earcinoma 였다. 9) 수술방법은 일측성 편엽절제술이 22례(64.7%)로 가장 많았다. 10) 수술후 합병증은 경도의 출혈이 5례(14.7%)였고, 다음이 일시적 사성 3례(8.8%)이었다.

• Journal of Life Science
• /
• v.19 no.11
• /
• pp.1514-1521
• /
• 2009

To evaluate the feasibility of cathepsin-B levels in preoperatively screening patients with thyroid cancer, we assigned these patients to either the thyroid cancer group (n=32) or the nodular hyperplasia group (n=7). Five healthy volunteers served as controls (n=5). We quantified cathepsin-B expressions in cancerous lesions with follicular carcinoma and hyperplastic lesions with nodular hyperplasia, and compared the degrees to those of normal thyroid tissue, which was obtained from matched contralateral lobe. The activity of serum cathepsin B was significantly higher in patients with thyroid carcinoma ($284.87{\pm}79.32$, ${\times}10^{-2}\;mU$) and those with nodular hyperplasia ($255.45{\pm}95.68$, ${\times}10^{-2}\;mU$) than compared to normal control ($168.94{\pm}15.10$, ${\times}10^{-2}\;mU$) (p<0.05). Based on the results of immunoassay, the concentrations of cathepsin B in the thyroid cancer group ($15.50{\pm}7.86\;ng/ml$) and the nodular hyperplasia group ($17.64{\pm}7.49\;ng/ml$) were higher than those of the control group ($4.85{\pm}0.61\;ng/ml$). The degree of cathepsin-B mRNA expression was significantly higher in cancerous or hyperplastic lesions than normal thyroid tissues from matched contralateral lobe with follicular carcinoma or non-neoplastic thyroid disease. Our results indicate that the activity of serum cathepsin B is a useful indicator in screening patients with nodular hyperplasia or neoplastic thyroid disease and it may be involved in the abnormal proliferation of cells.

• 건강소식
• /
• v.36 no.2
• /
• pp.24-25
• /
• 2012

우리나라의 암 발생률 1위인 위암 유병률이 0.4%인 반면 갑상선암의 유병률은 1% 정도로 높게 나타나고 있다. 최근 건강검진사업이 활성화 되면서 초음파를 통한 갑상선결절 진단율이 28.7%까지 보고되는 것을 보면 10명 중에 2~3명은 갑상선에 이상이 있음을 알 수 있다. 갑상선암은 20세 이하, 60세 이상에서는 드문 암으로 되어 있으며, 최근 전 국민 건강검진실시와 더불어 중년의 여성에서 진단되는 경우가 매우 증가하는 추세다. 목에 뭔가 만져지면서 이유 없이 붓거나, 이물감으로 음식물을 삼키기 어려울 때, 목소리가 이상할 때는 갑상선 전문의와의 상담이 중요하다.

• Journal of radiological science and technology
• /
• v.36 no.2
• /
• pp.149-155
• /
• 2013

The Korean Thyroid Association recommends fine-needle aspiration biopsy (FNAB) for nodules more than 0.5 cm in diameter. But nodules, smaller than 0.5 cm have been found in papillary carcinomas of the thyroid (PTC) at the health promotion center at SMC. We wanted to evaluate the ultrasonographic findings according to size of nodule in proven PTCs by FNAB, especially less than 0.5 cm. All nodules were classified into three groups by their longest diameter : less than 0.5 cm, more than 0.5 cm but less than 1 cm, and more than 1 cm. Sonographic findings suggesting malignancy were analyzed according to their size groups. Of 288 malignant nodules, 21.5 % (62/288) were less than 0.5 cm, 54.9 % (158/288) were more than 0.5 cm but less than 1 cm, 23.6 % (68/288) exceeded 1 cm. A taller-than-wide shape was observed in 90.3 % (56/62) of nodules less than 0.5 cm, and 48.5 % (33/68) of nodules exceeding 1 cm (p<0.001). There were no well-defined smooth nodules among nodules less than 0.5 cm, and spiculated or irregular margin nodules increased as the size increased (p=0.024). Nodules of size less than 0.5 cm did not showed hyper or isoechogenicity. Hypoechogenicity was greater than the marked hypoechogenicity in each group (p=0.034). Micro- or macro-calcifications were not founded in 77.4 % (48/62) of the nodule group sized less than 0.5 cm. From the small size of the group, micro- or macrocalcifications were observed 21.0 % (13/62), 48.1 % (76/158), 64.7 % (44/68), so the number of nodules containing micro- or macro-calcification increased as size increased (p<0.001). PTCs less than 0.5 cm in size on ultrasonography had taller than-wide shape, spiculated or irregular and ill-defined margins, and exhibited hypo and markedly hypoechogenicity, but microor macro-calcifications were not common. These ultrasonographic features of nodules less than 0.5 cm can be useful in reporting and guiding FNABs or follow-up exams.

• 대한두경부종양학회:학술대회논문집
• /
• 2004.11a
• /
• pp.263-263
• /
• 2004

• Journal of the Korean Society of Radiology
• /
• v.84 no.5
• /
• pp.985-998
• /
• 2023

Radiofrequency ablation (RFA) has been a representative, non-surgical treatment for benign thyroid nodules that cause cosmetic problems or compression symptoms. The procedure of RFA should be performed effectively and safely. This review discusses the patient selection, pre-procedure evaluation and planning, principles, devices, techniques, and complications with reference to the guidelines and research on thyroid RFA. In particular, this review will devote to introduce RFA techniques and to provide practical help in the implementation of this procedure.

• 대한핵의학회:학술대회논문집
• /
• 1986.05a
• /
• pp.119.2-119.2
• /
• 1986

• 대한두경부종양학회:학술대회논문집
• /
• 1996.11a
• /
• pp.264.1-264.1
• /
• 1996

• 대한핵의학회:학술대회논문집
• /
• 1972.11a
• /
• pp.66.1-66.1
• /
• 1972

• Journal of the Korean Society of Radiology
• /
• v.84 no.5
• /
• pp.1017-1030
• /
• 2023

Radiofrequency ablation (RFA) is a non-surgical treatment for symptomatic, benign thyroid nodules. This treatment works by heating and destroying the nodule tissue, which results in reduction of its size and alleviation of the symptoms involved. RFA is indicated for nodules which are confirmed to be benign on two or more cytological or histological examinations, and which result in clinical symptoms requiring medical treatment. It is associated with good short-term outcomes on one-year follow-up; however, 20%-30% of the nodules regrow after more than three years. Therefore, on the basis of long-term follow-up, management of regrowth is key to patient care following RFA. Regrowth is more likely to occur in nodules that are large in size prior to RFA, and in those with high or increased vascularity. Recently, new techniques such as hydrodissection, artery-first ablation, and venous ablation have been introduced to inhibit regrowth. In addition, appropriate criteria for additional RFA should be applied to manage regrowth and prolong its therapeutic effects. RFA is essentially an alternative to surgery; therefore, the ultimate goal of this procedure is to avoid surgery permanently, rather than to achieve temporary effects.